Long-term therapeutic aspirin could offer protection against cancer

Long-term aspirin use may offer protection against cancer, a recent study has found.

In analyzing data from 6 trials of daily low-dose aspirin in the primary prevention of vascular events (35,535 participants) and 51 clinical trials (including 34 randomized trials) of daily aspirin vs controls for the prevention of vascular events, researchers in Europe discovered that aspirin intake reduced cancer incidence from 3 years of use onward.

Previous studies have shown that daily aspirin use reduces the long-term risk of cancer death, but aspirin’s effects on cancer incidence and the time course of risk and benefit in primary prevention were unclear.

Daily aspirin reduced cancer deaths, especially from 5 years onward, resulting in 37% fewer nonvascular deaths overall compared with...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Oncology and tagged , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.